EMABling® platform

A proprietary technological platform of the LFB group, EMABling® is a fully integrated development program for the production of highly active antibodies and other recombinant proteins.

For monoclonal antibodies with high ADCC activity

EMABling® develops and produces recombinant monoclonal antibodies with an enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) activity due to an improved glycosylation profile for fucose. LFB’s research in this area has been based on the study of structure-function relationships for monoclonal antibodies and the importance of post-translational modifications to their functional activity (role of glycans).
LFB BIOMANUFACTURING’s customers can have access to EMABling® to manufacture their own recombinant high-ADCC mAbs.

Two complementary services for customers

Short feasibility assessment: LFB BIOMANUFACTURING can generate stable pools of recombinant YB2/0-E cells, deliver research-grade purified IgG ready for analysis and generate recombinant CHO version to perform comparison studies. This service of intermediate step of CLD enables the customer to optimize its roisk and manage its costs.

Full Cell Line Development : to this regard, LFB BIOMANUFACTURING proposes all the steps included in CLD, focusing on the delivery of a recombinant YB2/0-E cell line to manufacture low-fucose, high-ADCC mAbs. The manufacturing presents a good productivity profile. To perform these services, a license agreement is required.